AnPac Bio-Medical Science Co., Ltd. logo
AnPac Bio-Medical Science Co., Ltd. ANPC
$ 4.37 -1.58%

Annual report 2022
added 10-25-2025

report update icon

AnPac Bio-Medical Science Co., Ltd. Financial Ratios 2011-2025 | ANPC

Annual Financial Ratios AnPac Bio-Medical Science Co., Ltd.

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-1.6 -0.1 -0.7 -0.4 -0.9 - - - - - - -

P/S

- 0.9 2.9 3.6 3.6 - - - - - - -

EPS

-2.7 -8.7 -7.2 -11.3 -4.9 - - - - - - -

EV (Enterprise Value)

- 82.8 M 103 M 102 M 99.5 M 39.2 M - - - - - -

EBITDA per Share

-2.62 -7.95 -8.17 -9.67 -4.75 - - - - - - -

EV/EBITDA

-0.1 -0.7 - - - - - - - - -

PEG

- 0.17 - - - - - - - - -

P/B

-17.8 12.6 18.1 -2.5 -1.7 - - - - - - -

P/CF

-3.0 -0.2 -1.0 -0.8 -1.2 - - - - - - -

ROE %

745.05 2638.25 -2455.75 634.64 187.84 - - - - - - -

ROA %

-251.78 -175.87 -161.31 -190.74 -79.72 - - - - - - -

ROCE %

- 2491.60 -1486.03 674.10 233.50 - - - - - - -

Current Ratio

0.8 1.0 1.1 0.8 0.7 - - - - - - -

DSO

- 79.1 80.9 21.8 - - - - - - - -

DIO

34.5 25.5 15.0 11.3 2.0 - - - - - - -

DPO

238.2 154.7 94.0 54.3 - - - - - - - -

Operating Cycle

34.5 104.6 95.8 33.1 2.0 - - - - - - -

Cash Conversion Cycle

-203.8 -50.1 1.9 -21.2 2.0 - - - - - - -

All numbers in CNY currency

Quarterly Financial Ratios AnPac Bio-Medical Science Co., Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Current Ratio

- - - - 1.0 - 1.4 - 1.1 - - - 0.8 - - - 0.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

Multiples are an important financial analysis tool for the company AnPac Bio-Medical Science Co., Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Graybug Vision Graybug Vision
GRAY
$ 0.44 -11.23 % $ 9.65 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
$ 11.3 -10.17 % $ 12.2 K -
Galera Therapeutics Galera Therapeutics
GRTX
$ 0.14 -32.59 % $ 7.61 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 598.26 -6.45 % $ 45.3 B usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
$ 0.43 -16.75 % $ 25.8 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
$ 184.71 0.49 % $ 251 B cayman-islandsCayman-islands
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
$ 0.29 -18.52 % $ 27.3 M britainBritain
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M canadaCanada
Aeterna Zentaris Aeterna Zentaris
AEZS
$ 5.72 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M israelIsrael
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M usaUSA
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
$ 18.44 - $ 1.94 B canadaCanada
Kaleido Biosciences Kaleido Biosciences
KLDO
$ 0.29 -3.69 % $ 12.4 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
$ 2.19 - $ 105 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
$ 5.25 -0.38 % $ 977 M germanyGermany
Humanigen Humanigen
HGEN
$ 0.04 -81.12 % $ 4.28 M usaUSA
Aptinyx Aptinyx
APTX
$ 0.06 -39.0 % $ 4.57 M usaUSA
Tyme Technologies Tyme Technologies
TYME
$ 0.31 8.07 % $ 54 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 1.16 -1.69 % $ 27.9 M israelIsrael
Forward Pharma A/S Forward Pharma A/S
FWP
$ 2.64 -0.75 % $ 18.7 M danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
$ 0.39 - $ 26.5 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
$ 0.47 - $ 12.5 M belgiumBelgium
Brickell Biotech Brickell Biotech
BBI
$ 2.11 -5.38 % $ 6.06 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
$ 0.05 -15.0 % $ 3.04 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
$ 0.06 -55.98 % $ 2.15 M usaUSA
FibroGen FibroGen
FGEN
$ 11.04 0.33 % $ 1.07 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
$ 8.37 - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
$ 3.17 1.93 % $ 17.4 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 1.74 -0.63 % $ 4.38 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
$ 0.37 -10.95 % $ 876 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
$ 20.01 - $ 958 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
$ 49.55 -6.81 % $ 3.04 B usaUSA
Sierra Oncology Sierra Oncology
SRRA
$ 54.89 -0.05 % $ 1.34 B canadaCanada
Regulus Therapeutics Regulus Therapeutics
RGLS
$ 8.16 - $ 155 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Yunhong International Yunhong International
ZGYH
$ 10.31 0.10 % $ 92.2 M chinaChina